Compare
Alzamend Neuro, Inc. vs Inhibitor Therapeutics, Inc. vs Accustem Sciences Inc. vs Artelo Biosciences, Inc.
| Latest fiscal year | Alzamend Neuro, Inc. ALZN | Inhibitor Therapeutics, Inc. INTI | Accustem Sciences Inc. ACUT | Artelo Biosciences, Inc. ARTL |
|---|---|---|---|---|
| Year ended | 2026-04-30 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | n/a | n/a | n/a | n/a |
| Revenue growth (YoY) | n/a | n/a | n/a | n/a |
| Gross margin | n/a | n/a | n/a | n/a |
| Operating margin | n/a | n/a | n/a | n/a |
| Net margin | n/a | n/a | n/a | n/a |
| Net income | -$8.77M | -$3.30M | -$1.76M | -$12.88M |
| EPS (Diluted) | -$2.63 | -$0.02 | -$0.12 | -$12.52 |
| Operating cash flow | -$8.07M | -$3.23M | -$850.4K | -$8.52M |
| Free cash flow | n/a | n/a | n/a | n/a |
| Cash & equivalents | $710.7K | $2.38M | n/a | $600.0K |
| Total assets | $2.08M | $2.51M | $1.55M | $2.80M |
| Total liabilities | $1.35M | $3.80M | $4.95M | $4.07M |
| Shareholders' equity | $733.2K | -$1.29M | -$3.40M | -$1.27M |
| Return on year-end equity | n/m | n/a | n/a | n/a |
| Shares outstanding | 4.26M | 172.57M | 16.07M | 2.02M |
Revenue, most recent five fiscal years
| Fiscal year | Alzamend Neuro, Inc. | Inhibitor Therapeutics, Inc. | Accustem Sciences Inc. | Artelo Biosciences, Inc. |
|---|---|---|---|---|
| Latest | n/a | $0 Ended 2021-12-31 | n/a | n/a |
| 1 year earlier | n/a | $0 Ended 2020-12-31 | n/a | n/a |
| 2 years earlier | n/a | $0 Ended 2019-12-31 | n/a | n/a |
| 3 years earlier | n/a | $0 Ended 2018-12-31 | n/a | n/a |
| 4 years earlier | n/a | $0 Ended 2017-12-31 | n/a | n/a |